Microenvironmental Regulation of Tumor Progression and Metastasis

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2013 Nov 9

PMID 24202395

Citations 3910

Authors

Daniela F Quail

Johanna A Joyce

Affiliations

Soon will be listed here.

Abstract

Cancers develop in complex tissue environments, which they depend on for sustained growth, invasion and metastasis. Unlike tumor cells, stromal cell types within the tumor microenvironment (TME) are genetically stable and thus represent an attractive therapeutic target with reduced risk of resistance and tumor recurrence. However, specifically disrupting the pro-tumorigenic TME is a challenging undertaking, as the TME has diverse capacities to induce both beneficial and adverse consequences for tumorigenesis. Furthermore, many studies have shown that the microenvironment is capable of normalizing tumor cells, suggesting that re-education of stromal cells, rather than targeted ablation per se, may be an effective strategy for treating cancer. Here we discuss the paradoxical roles of the TME during specific stages of cancer progression and metastasis, as well as recent therapeutic attempts to re-educate stromal cells within the TME to have anti-tumorigenic effects.

Citing Articles

SIGLEC1 has the potential to be an immune-related prognostic indicator in colon adenocarcinoma: a study based on transcriptomic data and Mendelian randomization analysis.

Gu J, Wang Y, Zhang H, Gu H, Zhu H Discov Oncol. 2025; 16(1):324.

PMID: 40088346 DOI: 10.1007/s12672-025-02093-2.

Intratumoral and peritumoral CT radiomics in predicting anaplastic lymphoma kinase mutations and survival in patients with lung adenocarcinoma: a multicenter study.

Chen W, Lin G, Feng Y, Chen Y, Li Y, Li J Cancer Imaging. 2025; 25(1):35.

PMID: 40083024 PMC: 11907895. DOI: 10.1186/s40644-025-00856-2.

Prospect of extracellular vesicles in tumor immunotherapy.

Xia W, Tan Y, Liu Y, Xie N, Zhu H Front Immunol. 2025; 16:1525052.

PMID: 40078996 PMC: 11897508. DOI: 10.3389/fimmu.2025.1525052.

Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment?.

Kim J, Li J, Wei J, Lim S Immune Netw. 2025; 25(1):e13.

PMID: 40078783 PMC: 11896657. DOI: 10.4110/in.2025.25.e13.

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.

Ding T, He L, Lin G, Xu L, Zhu Y, Wang X Chin J Cancer Res. 2025; 37(1):90-114.

PMID: 40078560 PMC: 11893346. DOI: 10.21147/j.issn.1000-9604.2025.01.07.

References

Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Ruegg C, Christofori G . Myeloid cells contribute to tumor lymphangiogenesis. PLoS One. 2009; 4(9):e7067. PMC: 2738969. DOI: 10.1371/journal.pone.0007067. View

Naslund T, Gehrmann U, Qazi K, Karlsson M, Gabrielsson S . Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 2013; 190(6):2712-9. DOI: 10.4049/jimmunol.1203082. View

Amirkhosravi A, Meyer T, Chang J, Amaya M, Siddiqui F, Desai H . Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002; 87(6):930-6. View

Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E . Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151(7):1542-56. DOI: 10.1016/j.cell.2012.11.024. View

Magnon C, Hall S, Lin J, Xue X, Gerber L, Freedland S . Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341(6142):1236361. DOI: 10.1126/science.1236361. View

Mantovani G, Maccio A, Pisano M, Versace R, Lai P, Esu S . Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 1997; 71(5):724-31. DOI: 10.1002/(sici)1097-0215(19970529)71:5<724::aid-ijc6>3.0.co;2-t. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

11.

Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S . Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105(18):6620-5. PMC: 2365563. DOI: 10.1073/pnas.0710516105. View

12.

Zeisberg E, Potenta S, Xie L, Zeisberg M, Kalluri R . Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67(21):10123-8. DOI: 10.1158/0008-5472.CAN-07-3127. View

13.

Orr B, Riddick A, Stewart G, Anderson R, Franco O, Hayward S . Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate. Oncogene. 2011; 31(9):1130-42. PMC: 3307063. DOI: 10.1038/onc.2011.312. View

14.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

15.

Blatner N, Mulcahy M, Dennis K, Scholtens D, Bentrem D, Phillips J . Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 2012; 4(164):164ra159. PMC: 3762575. DOI: 10.1126/scitranslmed.3004566. View

16.

Beaugerie L, Svrcek M, Seksik P, Bouvier A, Simon T, Allez M . Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145(1):166-175.e8. DOI: 10.1053/j.gastro.2013.03.044. View

17.

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

18.

Sharma P, Wagner K, Wolchok J, Allison J . Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011; 11(11):805-12. PMC: 3426440. DOI: 10.1038/nrc3153. View

19.

de Visser K, Korets L, Coussens L . De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005; 7(5):411-23. DOI: 10.1016/j.ccr.2005.04.014. View

20.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View